FUJIFILM Diosynth Biotechnologies and NeuExcell Therapeutics enter manufacturing agreement to rapidly advance NXL-001, a potential neuro-regeneration gene therapy to treat ischemic cortical stroke

FUJIFILM Diosynth Biotechnologies and NeuExcell Therapeutics enter manufacturing agreement to rapidly advance NXL-001, a potential neuro-regeneration gene therapy to treat ischemic cortical stroke


Excerpt

The two companies have entered a manufacturing agreement for NXL-001, under which FUJIFILM will be tasked with providing essential drug substance and drug product manufacturing under accelerated timelines at its manufacturing facility in College Station, Texas, for NeuExcell’s first in-human clinical studies. This will hopefully facilitate a possible treatment for patients suffering from ischemic cortical stroke.

Article

As part of the agreement, FUJIFILM will be responsible for manufacturing essential drug substances and drug products in its cGMP mammalian manufacturing facility in Texas for NeuExcell’s in-human clinical trials. 

Gerry Farrell, chief operating officer at FUJIFILM Diosynth Biotechnologies, Texas site, expressed the company’s commitment to helping NeuExcell reach the full potential of their innovative technology platform on accelerated timelines, adding that “[it] is an honour for FDB to play a role helping to bring a treatment to patients around the world who suffer from ischemic cortical stroke.”

“Securing reliable biomanufacturing is essential and we are grateful to be able to advance the NXL-001 program immediately in FUJIFILM Diosynth Biotechnologies’ state-of-the-art manufacturing facility,” commented Jie Xu, Co-Founder and Head of Discovery at NeuExcell.

About NeuExcell Therapeutics

Headquartered in Pennsylvania, USA, NeuExcell is an early-stage gene technology company committed to developing solutions for a range of neuro-degenerative diseases and CNS injuries. The company has also developed a potentially disruptive neural repair technology. 

About FUJIFILM Diosynth Biotechnologies

FUJIFILM Diosynth Biotechnologies is a Biologics Contract Development and Manufacturing Organization (CDMO) with experience in the development of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures. The company provides services ranging from cell line development to process development, analytical development, clinical and FDA-approved commercial manufacturing. For more information, visit www.fujifilmdiosynth.com.

(Source: Cision, 13th September 2021)


Excerpt

The two companies have entered a manufacturing agreement for NXL-001, under which FUJIFILM will be tasked with providing essential drug substance and drug product manufacturing under accelerated timelines at its manufacturing facility in College Station, Texas, for NeuExcell’s first in-human clinical studies. This will hopefully facilitate a possible treatment for patients suffering from ischemic cortical stroke.

Article

As part of the agreement, FUJIFILM will be responsible for manufacturing essential drug substances and drug products in its cGMP mammalian manufacturing facility in Texas for NeuExcell’s in-human clinical trials. 

Gerry Farrell, chief operating officer at FUJIFILM Diosynth Biotechnologies, Texas site, expressed the company’s commitment to helping NeuExcell reach the full potential of their innovative technology platform on accelerated timelines, adding that “[it] is an honour for FDB to play a role helping to bring a treatment to patients around the world who suffer from ischemic cortical stroke.”

“Securing reliable biomanufacturing is essential and we are grateful to be able to advance the NXL-001 program immediately in FUJIFILM Diosynth Biotechnologies’ state-of-the-art manufacturing facility,” commented Jie Xu, Co-Founder and Head of Discovery at NeuExcell.

About NeuExcell Therapeutics

Headquartered in Pennsylvania, USA, NeuExcell is an early-stage gene technology company committed to developing solutions for a range of neuro-degenerative diseases and CNS injuries. The company has also developed a potentially disruptive neural repair technology. 

About FUJIFILM Diosynth Biotechnologies

FUJIFILM Diosynth Biotechnologies is a Biologics Contract Development and Manufacturing Organization (CDMO) with experience in the development of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures. The company provides services ranging from cell line development to process development, analytical development, clinical and FDA-approved commercial manufacturing. For more information, visit www.fujifilmdiosynth.com.

(Source: Cision, 13th September 2021)


Excerpt

The two companies have entered a manufacturing agreement for NXL-001, under which FUJIFILM will be tasked with providing essential drug substance and drug product manufacturing under accelerated timelines at its manufacturing facility in College Station, Texas, for NeuExcell’s first in-human clinical studies. This will hopefully facilitate a possible treatment for patients suffering from ischemic cortical stroke.

Article

As part of the agreement, FUJIFILM will be responsible for manufacturing essential drug substances and drug products in its cGMP mammalian manufacturing facility in Texas for NeuExcell’s in-human clinical trials. 

Gerry Farrell, chief operating officer at FUJIFILM Diosynth Biotechnologies, Texas site, expressed the company’s commitment to helping NeuExcell reach the full potential of their innovative technology platform on accelerated timelines, adding that “[it] is an honour for FDB to play a role helping to bring a treatment to patients around the world who suffer from ischemic cortical stroke.”

“Securing reliable biomanufacturing is essential and we are grateful to be able to advance the NXL-001 program immediately in FUJIFILM Diosynth Biotechnologies’ state-of-the-art manufacturing facility,” commented Jie Xu, Co-Founder and Head of Discovery at NeuExcell.

About NeuExcell Therapeutics

Headquartered in Pennsylvania, USA, NeuExcell is an early-stage gene technology company committed to developing solutions for a range of neuro-degenerative diseases and CNS injuries. The company has also developed a potentially disruptive neural repair technology. 

About FUJIFILM Diosynth Biotechnologies

FUJIFILM Diosynth Biotechnologies is a Biologics Contract Development and Manufacturing Organization (CDMO) with experience in the development of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures. The company provides services ranging from cell line development to process development, analytical development, clinical and FDA-approved commercial manufacturing. For more information, visit www.fujifilmdiosynth.com.

(Source: Cision, 13th September 2021)


Excerpt

The two companies have entered a manufacturing agreement for NXL-001, under which FUJIFILM will be tasked with providing essential drug substance and drug product manufacturing under accelerated timelines at its manufacturing facility in College Station, Texas, for NeuExcell’s first in-human clinical studies. This will hopefully facilitate a possible treatment for patients suffering from ischemic cortical stroke.

Article

As part of the agreement, FUJIFILM will be responsible for manufacturing essential drug substances and drug products in its cGMP mammalian manufacturing facility in Texas for NeuExcell’s in-human clinical trials. 

Gerry Farrell, chief operating officer at FUJIFILM Diosynth Biotechnologies, Texas site, expressed the company’s commitment to helping NeuExcell reach the full potential of their innovative technology platform on accelerated timelines, adding that “[it] is an honour for FDB to play a role helping to bring a treatment to patients around the world who suffer from ischemic cortical stroke.”

“Securing reliable biomanufacturing is essential and we are grateful to be able to advance the NXL-001 program immediately in FUJIFILM Diosynth Biotechnologies’ state-of-the-art manufacturing facility,” commented Jie Xu, Co-Founder and Head of Discovery at NeuExcell.

About NeuExcell Therapeutics

Headquartered in Pennsylvania, USA, NeuExcell is an early-stage gene technology company committed to developing solutions for a range of neuro-degenerative diseases and CNS injuries. The company has also developed a potentially disruptive neural repair technology. 

About FUJIFILM Diosynth Biotechnologies

FUJIFILM Diosynth Biotechnologies is a Biologics Contract Development and Manufacturing Organization (CDMO) with experience in the development of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures. The company provides services ranging from cell line development to process development, analytical development, clinical and FDA-approved commercial manufacturing. For more information, visit www.fujifilmdiosynth.com.

(Source: Cision, 13th September 2021)


Excerpt

The two companies have entered a manufacturing agreement for NXL-001, under which FUJIFILM will be tasked with providing essential drug substance and drug product manufacturing under accelerated timelines at its manufacturing facility in College Station, Texas, for NeuExcell’s first in-human clinical studies. This will hopefully facilitate a possible treatment for patients suffering from ischemic cortical stroke.

Article

As part of the agreement, FUJIFILM will be responsible for manufacturing essential drug substances and drug products in its cGMP mammalian manufacturing facility in Texas for NeuExcell’s in-human clinical trials. 

Gerry Farrell, chief operating officer at FUJIFILM Diosynth Biotechnologies, Texas site, expressed the company’s commitment to helping NeuExcell reach the full potential of their innovative technology platform on accelerated timelines, adding that “[it] is an honour for FDB to play a role helping to bring a treatment to patients around the world who suffer from ischemic cortical stroke.”

“Securing reliable biomanufacturing is essential and we are grateful to be able to advance the NXL-001 program immediately in FUJIFILM Diosynth Biotechnologies’ state-of-the-art manufacturing facility,” commented Jie Xu, Co-Founder and Head of Discovery at NeuExcell.

About NeuExcell Therapeutics

Headquartered in Pennsylvania, USA, NeuExcell is an early-stage gene technology company committed to developing solutions for a range of neuro-degenerative diseases and CNS injuries. The company has also developed a potentially disruptive neural repair technology. 

About FUJIFILM Diosynth Biotechnologies

FUJIFILM Diosynth Biotechnologies is a Biologics Contract Development and Manufacturing Organization (CDMO) with experience in the development of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures. The company provides services ranging from cell line development to process development, analytical development, clinical and FDA-approved commercial manufacturing. For more information, visit www.fujifilmdiosynth.com.

(Source: Cision, 13th September 2021)

Comments

Leave A Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

bag